Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
Diabetes|May 22, 2019
Sodium-Glucose Cotransporter 2 Inhibitors: A Case Study in Translational ResearchAmber L Beitelshees, Bruce R Leslie, Simeon I Taylor
The Journal of Clinical Investigation|January 19, 2021
Pharmacological treatment of hyperglycemia in type 2 diabetesSimeon I Taylor, Zhinous Shahidzadeh Yazdi, Amber L Beitelshees
The Lancet. Diabetes & Endocrinology|October 6, 2019
SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risksSimeon I Taylor, Jenny E Blau, Kristina I Rother, et al.
Annals of Internal Medicine|September 17, 2019
Sodium-Glucose Cotransporter-2 Inhibitors: Lack of a Complete History Delays DiagnosisBruce R Leslie, Leslie E Gerwin, Simeon I Taylor
The Journal of Clinical Endocrinology and Metabolism|March 14, 2024
Critical Role for 24-Hydroxylation in Homeostatic Regulation of Vitamin D MetabolismZhinous Shahidzadeh Yazdi, Elizabeth A Streeten, Hilary B Whitlatch, et al.
Medrxiv : the Preprint Server for Health Sciences|July 10, 2023
Critical Role for 24-Hydroxylation in Homeostatic Regulation of Vitamin D MetabolismZhinous Shahidzadeh Yazdi, Elizabeth A Streeten, Hilary B Whitlatch, et al.
JCEM Case Reports|July 1, 2024
Value of Vitamin D Metabolite Ratios in 3 Patients as Diagnostic Criteria to Assess Vitamin D StatusZhinous Shahidzadeh Yazdi, Elizabeth A Streeten, Hilary B Whitlatch, et al.
Medrxiv : the Preprint Server for Health Sciences|May 22, 2023
Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse effects on 1,25-dihydroxyvitamin D and PTHZhinous Shahidzadeh Yazdi, Elizabeth A Streeten, Hilary B Whitlatch, et al.
The Journal of Clinical Endocrinology and Metabolism|September 22, 2023
Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTHZhinous Shahidzadeh Yazdi, Elizabeth A Streeten, Hilary B Whitlatch, et al.
Heart Failure Reviews|March 21, 2008
Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure managementAmber L Beitelshees, Issam Zineh
Pageof 15